ZIM Laboratories Limited develops and manufactures pharmaceutical products, including differentiated formulations and drug-delivery solutions for domestic and international markets. Growing healthcare demand, pharmaceutical outsourcing, and expansion into regulated and emerging markets provide opportunities for growth. Regulatory approvals, product development, manufacturing capacity, pricing pressure, export demand, and competition remain important factors.
| Market cap | Sales (TTM) | Net profit (TTM) | P/E | EPS (TTM) | P/B | ROE | ROE previous year | ROCE | Debt / equity | Free cash flow | EV / EBITDA | Beta |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ₹740 cr | ₹397 cr | ₹4 cr | 168.5 | 0.82 | 2.50 | 2.1% | 5.0% | 5.5% | 0.42 | ₹11 cr | 21.1 | 0.75 |
| Quarter | Sales ₹ cr | Net profit ₹ cr | EPS | EPS YoY | Sales YoY | Net margin |
|---|---|---|---|---|---|---|
| Jun 2026 | 94 | -4 | -0.75 | — | +31.2% | -4.3% |
| Mar 2026 | 105 | 4 | 0.76 | -24.8% | -3.2% | 3.5% |
| Dec 2025 | 109 | 4 | 0.90 | +9.8% | +12.8% | 4.0% |
| Sep 2025 | 89 | -0 | -0.09 | -118.4% | -3.7% | -0.5% |
| Jun 2025 | 72 | -2 | -0.38 | -311.1% | -12.3% | -2.6% |
| Mar 2025 | 109 | 5 | 1.01 | -39.2% | -7.8% | 4.5% |
| Dec 2024 | 96 | 4 | 0.82 | -16.3% | +0.0% | 4.2% |
| Sep 2024 | 92 | 2 | 0.49 | -42.4% | +7.4% | 2.6% |
| Check | Result |
|---|---|
| Latest quarter EPS up 25%+ on a year ago | — Not assessable |
| EPS growth accelerating over 3 quarters | — Not assessable |
| Sales up 25%+, or sales growth accelerating | ✓ Pass |
| Annual EPS up 25%+ in each of the last 2 years | ✗ Fail |
| Net margin above the same quarter last year | ✗ Fail |
| Method | Checks | Score | Verdict |
|---|---|---|---|
| Minervini | ✓ Close above the 150- and 200-day averages ✓ 150-day above 200-day ✓ 200-day rising for a month ✓ 50-day above the 150- and 200-day ✓ Close above the 50-day ✓ At least 25% above the 52-week low · low 60.26 ✓ Within 25% of the 52-week high · high 152.63 ✓ RS percentile 70 or more · RS 92 Trend template - the gate, measured: a modest 21-day edge. | 8/8 | Pass |
| Weinstein | Stan Weinstein's stage analysis on the 30-week moving average. | Stage 2 - advancing | |
| CAN SLIM | — C latest quarter EPS up 25%+ ✗ A annual EPS up 25%+ in each of the last 2 years · O'Neil asks 3; ~2 held ✓ N within 15% of the 52-week high · high 152.63 ✓ S more volume on up days than down days (50 sessions) · 2.22x ✓ L RS percentile 80 or more · RS 92 — I institutional sponsorship rising · shareholding not collected yet ✓ M market in an uptrend (40%+ of stocks above their 200-day) · breadth 45% William O'Neil's growth-leader checklist. | 4/5 | Strong |
| Darvas | ✓ Box top confirmed (3 sessions below the new high) · top 159.81 ✗ Box bottom confirmed (3 sessions holding) · bottom 138.50 ✗ Close above the box top · close 138.17 ✗ Volume at least 1.5x its 50-day average · 0.4x Nicolas Darvas's box: buy the breakout above a confirmed box after a new high. | 47/100 | In box |
| Turtle | ✗ Close above the prior 55-session high · 159.81 ✗ Close above the prior 20-session high · 159.81 ✗ Close below the prior 20-session low · 130.20 Donchian channel breakout - the Turtle traders' entry. | No signal | |
| Greenblatt | — Earnings yield (EBITDA / EV) · 4.7% — Return on capital (ROCE) · 5.5% Joel Greenblatt's Magic Formula: good businesses at good prices, ranked across all companies. Earnings yield uses EBITDA, as EBIT is not held separately. | 13/100 | Weak |
| Graham | ✗ Price at or below the Graham number · Graham number 31.93 ✗ P/E 15 or less · P/E 168.5 ✗ P/B 1.5 or less (or P/E x P/B 22.5 or less) · P/B 2.50 ✗ Current ratio 2 or more · 1.45 — 10 years of positive earnings, 20 of dividends · history not held Benjamin Graham's defensive-investor tests. | 23/100 | Expensive |
| Piotroski | ✓ Profitable (ROA > 0) ✓ Operating cash flow positive ✗ ROA rising ✓ Cash flow above net profit (earnings quality) ✓ Long-term debt / assets falling ✓ Current ratio rising · 1.45 ✗ No new shares issued ✗ Margin rising (net margin) ✗ Asset turnover rising Joseph Piotroski's F-score, FY 2025 -> 2026. | 5/9 | Average |
| Stock | 1M % | 3M % | 6M % | 1Y % | 3Y % | 5Y % | P/E | P/B | ROE % | ROCE % | ROA % | D/E | EV/EBITDA | ₹ Cr | Sales TTM ₹ Cr | Profit TTM ₹ Cr | EPS | Beta |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ZIMLAB this stock | +2.0 | +14.2 | +73.3 | +101.9 | +17.5 | — | 168.5 | 2.50 | 2.1 | 5.5 | — | 0.42 | 21.1 | 740 | 397 | 4 | 0.8 | 0.75 |
| BLISSGVS | -8.0 | +29.9 | +147.2 | +312.3 | +606.5 | +476.9 | 48.7 | 5.57 | 11.5 | 16.8 | — | 0.00 | 29.3 | 6,650 | 1,005 | 142 | 12.9 | 1.10 |
| VENUSREM | +0.7 | -5.9 | +55.8 | +252.6 | +518.8 | +242.4 | 18.3 | 3.21 | 16.8 | 21.9 | — | 0.00 | 13.7 | 2,130 | 811 | 116 | 86.9 | 0.88 |
| INDSWFTLAB | -5.7 | +50.4 | +153.3 | +247.2 | +287.1 | +472.2 | 51.6 | 2.21 | 3.2 | 3.9 | — | 0.01 | 33.4 | 3,056 | 665 | 57 | 6.8 | 0.78 |
| MOREPENLAB | +0.5 | +108.6 | +194.2 | +152.6 | +242.7 | +132.7 | 47.5 | 5.34 | 7.9 | 10.1 | — | 0.16 | 40.2 | 6,657 | 1,951 | 140 | 2.6 | 1.46 |
| SHILPAMED | -14.2 | +40.1 | +113.1 | +146.1 | +421.3 | +189.7 | 57.3 | 6.61 | 9.8 | 11.4 | — | 0.25 | — | 17,130 | 1,682 | 297 | 15.3 | 0.87 |
| RUBICON | -15.1 | -1.7 | +60.3 | +140.3 | — | — | 83.8 | 19.08 | 22.4 | — | — | 0.20 | 61.3 | 24,587 | 1,936 | 288 | 17.7 | 0.34 |
| LAURUSLABS | +5.9 | +32.7 | +83.2 | +129.9 | +421.9 | +235.3 | 88.9 | 21.09 | 18.2 | 17.9 | — | 0.45 | 62.0 | 1.12L | 8,839 | 1,252 | 23.3 | 0.74 |
| ACUTAAS | -5.4 | -11.0 | +35.0 | +97.5 | — | — | 69.0 | 16.11 | 24.0 | 31.7 | — | 0.02 | 49.9 | 26,636 | 1,462 | 387 | 47.2 | 0.77 |
| IOLCP | -9.8 | +17.8 | +108.9 | +87.8 | +99.0 | +56.2 | 32.0 | 2.99 | 7.9 | 10.7 | — | 0.07 | 20.7 | 5,376 | 2,524 | 168 | 5.7 | 1.13 |
| SENORES | -10.6 | -9.5 | +37.4 | +75.3 | — | — | 44.1 | 6.18 | 14.1 | 15.3 | — | 0.35 | 29.5 | 5,773 | 692 | 131 | 28.4 | 0.95 |